Processes for preparing crystalline and amorphous mupirocin...

Details Processes for preparing crystalline and amorphous mupirocin... Processes for preparing crystalline and amorphous mupirocin...

2002-11-06

2010-06-15

Richter, Johann R (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S557000, C514S724000

Reexamination Certificate

active

07737177

ABSTRACT:
Processes are provided for preparing mupirocin calcium dihydrate from pseudomonic acid in a two phase system by using an organic carboxylate. A highly pure composition of amorphous mupirocin calcium is provided, and processes for its preparation by solvent removal, lyophilization and precipitation with use of an anti-solvent. Pharmaceutical compositions of amorphous form, and methods of using them to treat infections are also provided. Also provided are combined processes for preparing mupirocin calcium dihydrate and amorphous, by producing amorphous form first, followed by conversion of amorphous form into the dihydrate through crystallization from an aqueous solution. Also provided are processes for removing the water of crystallization of the dihydrate to obtain mupirocin calcium anhydrate.

REFERENCES:
patent: 3954872 (1976-05-01), Koppe et al.
patent: 3977943 (1976-08-01), Barrow et al.
patent: 4071536 (1978-01-01), Barrow et al.
patent: 4222942 (1980-09-01), O'Hanlon et al.
patent: 4289703 (1981-09-01), Barrow et al.
patent: 4524075 (1985-06-01), Oduro-Yeboah
patent: 4639534 (1987-01-01), Curzons
patent: 4786742 (1988-11-01), Curzons
patent: 4790989 (1988-12-01), Hunter et al.
patent: 4879287 (1989-11-01), Orr et al.
patent: 4916155 (1990-04-01), Baker et al.
patent: 5191093 (1993-03-01), Baker et al.
patent: 5405762 (1995-04-01), Takahashi et al.
patent: 5436266 (1995-07-01), Baker et al.
patent: 5569672 (1996-10-01), Baker et al.
patent: 5594026 (1997-01-01), Greenway et al.
patent: 6001870 (1999-12-01), Henkel
patent: 6231875 (2001-05-01), Sun et al.
patent: 6245921 (2001-06-01), Barta et al.
patent: 6280593 (2001-08-01), Wiese et al.
patent: 6489358 (2002-12-01), Lavon et al.
patent: 6506591 (2003-01-01), Szell et al.
patent: 2002/0004063 (2002-01-01), Zhang
patent: 2002/0028227 (2002-03-01), Yu et al.
patent: 2002/0028843 (2002-03-01), Lavon et al.
patent: 2002/0035061 (2002-03-01), Krieger et al.
patent: 2004/0039049 (2004-02-01), Weisman et al.
patent: 870855 (1979-03-01), None
patent: 2227739 (1973-01-01), None
patent: 0 005 614 (1979-11-01), None
patent: 0 251 434 (1988-01-01), None
patent: 1 174 133 (2002-01-01), None
patent: 1 384 721 (2004-01-01), None
patent: 1395907 (1975-05-01), None
patent: 1577730 (1977-10-01), None
patent: 1577545 (1980-10-01), None
patent: 52-70083 (1977-06-01), None
patent: 00/46388 (2000-08-01), None
patent: 00/46389 (2000-08-01), None
STN online, file DRUGU, Acc. No. 1984-01924 (Schauwecker, Pharm Int. (1983), No. 4, pp. 178-183), Abstract.
STN online, file DRUGU, Acc. No. 1987-14971 (Brandstaetter et al., Sci. Pharma. (1986), vol. 54, No. 1, pp. 1-10), Abstract.
European Pharmacopoeia, 4thEd. pp. 1602-1604, Strasbourg, (2001).
Clayton et al. “The Structure and Configuartion of Pseudomonic Acid C” Tetrahedron Letters 1980, vol. 21, pp. 881-884.
O'Hanlon et al. “The Chemistry of Pseudomonic Acid. Part 6. Structure and Preparation of Pseudomonic Acid D” Journal Chemical Society, Perkin Trans. I 1983, pp. 2655-2657.
Feline et al. “Pseudomonic acid. Part 2. Biosynthesis of Pseudomonic Acid A.” Journal Chemical Society, Perkin Trans. I. 1977, pp. 309-318.
Mantle et al. “Radiolabelling of the monate moiety in the study of pseudomonic acid biosynthesis.” FEMS Microbiol. Lett. 1989, vol. 59, No. 12, pp. 55-58.
Martin et al. “Biosynthetic studies on pseudomonic acid (mupirocin), a novel antibiotic metabolite ofPseudomonas fluorescens.” Journal Chemical Society, Perkin Trans. I. 1989, pp. 207-209.
Ward et al. “Mupirocin-A review of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use,” Drugs. 1986, vol. 32, No. 5, pp. 425-444.
Hughes et al. “Interaction of pseudomonic acid A withEscherichia coliB isoleucyl-tRNA synthetase.” Biochemical Journal. 1980, vol. 191, pp. 209-219.
Chain et al. “Pseudomonic Acid. Part 3. Structure of Pseudomonic Acid B” Journal Chemical Society, Perkin Trans. I. 1977, p. 318-322.
Chain et al. “Structure of Pseudomonic Acid, an Antibiotic fromPseudomonas fluorescens.” Journal of the Chemical Society, Chemical Communications. Jan. 1974, No. 1, pp. 847-848.
Alexander et al. “The Chemistry of Pseudomonic Acid. Part 1. The Absolute Configuration of Pseudomonic Acid A.” Journal of the Chemical Society, Perkin Transactions I, Organic and Bio-organic Chemistry. 1978, pp. 561-565.
Palleroni. “Psuedomonaceae.” Bergey's Manual of Systematic Bacteriology. 1984, vol. 1, pp. 141-219.
Harry G. Brittain (Ed.) (1999) “Polymorphism in Pharmaceutical Solids” Drugs and the Pharmaceutical Sciences vol. 95, pp. 183-226 Marcel Dekker, Inc. New York, New York.
Ben Zion Dolitzky et al. Process for Preparing Nateglinide and Intermediates Thereof U.S. Appl. No. 60/413,622, filed Sep. 25, 2002.
Harry G. Brittain (Ed.) (1999) “Polymorphism in Pharmaceutical Solids” Drugs and the Pharmaceutical Sciences vol. 95, pp. 395-419 Marcel Dekker, Inc. New York, New York.
Fuller et al. “Pseudomonic Acid: an Antibiotic produced byPseudomonas fluorescens” Nature, vol. 234, p. 416-417, (1971).

Affiliated with

Also associated with

Rating

Processes for preparing crystalline and amorphous mupirocin... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Processes for preparing crystalline and amorphous mupirocin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Processes for preparing crystalline and amorphous mupirocin... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4247661